ESMO 2024: Treatment of uHCC - Episode 2

Treatment Decisions Based on BLCL Stage

, , , , ,

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Video content above is prompted by the following:

  • What are the current treatment options, and what factors drive your treatment decision?
    • Atezolizumab plus bevacizumab (ImBRAVE 150 – Kudo et al. Liver Cancer. 2022)
    • Durvalumab plus tremelimumab (HIMALAYA – Sangro et al. Ann Oncol. 2024)